MedTrace Logo

First-in-man Study of Single and Multiple Ascending Doses of a New Drug for Neurological Disorders

NCT02702648 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 128

Last updated 2018-07-10

No results posted yet for this study

Summary

The primary purpose of this first-in-man study is to investigate whether a new drug for neurological disorders is safe and well-tolerated when administered orally to healthy adults

Conditions

  • Healthy Subjects

Interventions

DRUG

AC-082

Hard gelatin capsules for oral administration

DRUG

Placebo

Matched placebo capsules for oral administration

Sponsors & Collaborators

  • Idorsia Pharmaceuticals Ltd.

    lead INDUSTRY

Principal Investigators

  • Karine Litherland, PhD · Actelion

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-02-01
Primary Completion
2017-03-06
Completion
2017-03-06

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02702648 on ClinicalTrials.gov